No Data
Zhejiang Medicine's (SHSE:600216) Underlying Earnings Growth Outpaced the Favorable Return Generated for Shareholders Over the Past Year
Zhejiang Medicine (600216.SH): Guotou High Technology plans to reduce its shareholding by no more than 1%.
Gelonghui, on March 20, announced that Zhejiang Medicine (600216.SH) stated that within three months after 15 trading days from the release of this announcement, Guotou Gaoke plans to reduce its shareholding by a total of no more than 9,616,377 shares, which is no more than 1% of the company's total share capital.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Biggest Owners Are Individual Investors Who Got Richer After Stock Soared 4.8% Last Week
Zhejiang Medicine Obtains Registration for Intravenous Solution
Zhejiang Medicine Subsidiary Passes US FDA Inspection for Antibiotic
The Three-year Shareholder Returns and Company Earnings Persist Lower as Zhejiang Medicine (SHSE:600216) Stock Falls a Further 4.0% in Past Week
